Cargando…
Lai C, Ranpura V, Wu C, et al. Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Adv. 2019;3(7):980-983.
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
American Society of Hematology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560351/ https://www.ncbi.nlm.nih.gov/pubmed/31160296 http://dx.doi.org/10.1182/bloodadvances.2019000319 |
Ejemplares similares
-
Park EJ, Prajuabjinda O, Soe ZY, et al. Exosomal regulation of lymphocyte homing to the gut. Blood Adv. 2019;3(1):1-11.
Publicado: (2019) -
Park EJ, Prajuabjinda O, Soe ZY, et al. Exosomal regulation of lymphocyte homing to the gut. Blood Adv. 2019;3(1):1-11.
Publicado: (2019) -
Manasanch EE, Han G, Mathur R, et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019;3(15):2400-2408.
Publicado: (2019) -
Abraham AA, John TD, Keller MD, et al. Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Adv. 2019;3(14):2057-2068.
Publicado: (2019) -
Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297.
Publicado: (2019)